Phase 3 evaluation of the efficacy and safety of abicipar compared with ranibizumab for treatment of neovascular age-related macular degeneration (nAMD)
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI